{
    "clinical_study": {
        "@rank": "63844", 
        "arm_group": [
            {
                "arm_group_label": "Naftopidil", 
                "arm_group_type": "Active Comparator", 
                "description": "Naftopidil 75mg once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate Efficacy and Safety of oral intake of Naftopidil\n      75mg  once daily for the improving clearance of ureteral or renal stones."
        }, 
        "brief_title": "Naftopidil 75mg for Improving Clearance of Urinary Stones", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kidney Calculi", 
            "Ureter Calculi"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Calculi", 
                "Kidney Calculi", 
                "Ureteral Calculi", 
                "Ureterolithiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective, Single-center, Double blind, Randomized controlled trial\n\n      Treatment\n\n      - Oral Naftopidil 75 mg once daily are given to the patients who are scheduled for shockwave\n      lithotripsy (ESWL) because of ureteral or renal stones.\n\n      Follow up Assessments including X-ray(KUB), visual analogue pain scale, are done 2, 4, and 6\n      weeks after the ESWL."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Radio-opaque (identifiable in KUB) ureter or kidney calculi\n\n          -  size criteria is from 5mm to 15mm\n\n        Exclusion Criteria:\n\n          -  Symptomatic acute urinary tract infection during the run-in period\n\n          -  severe hydronephrosis\n\n          -  2 or more urinary stones\n\n          -  Radiolucent (non-visible in KUB) stone\n\n          -  recent intervention for the urinary stone within 6 month\n\n          -  Patients who have ureteral stent\n\n          -  over 2.0 mg/dl of serum creatinine level\n\n          -  severe hepatic dysfunction\n\n          -  orthostatic hypotension\n\n          -  current usage of alpha-adrenergic blocker or calcium channel blocker\n\n          -  Pregnant or nursing women\n\n          -  Age under 15 year\n\n          -  severe or uncontrolled medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011737", 
            "org_study_id": "SMC2013-08-066"
        }, 
        "intervention": {
            "arm_group_label": "Naftopidil", 
            "intervention_name": "naftopidil 75mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Naftopidil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Medical Expulsive therapy", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "deokhyun.han@gmail.com", 
                "last_name": "Deok Hyun Han, M.D.", 
                "phone": "+82-10-9933-5125"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Deok Hyun Han, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Seol Ho Choo, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effectiveness and Safety of Naftopidil 75mg for Improving Clearance of Ureteral and Renal Stones After Shockwave Lithotripsy: Prospective Randomized Controlled Study", 
        "other_outcome": [
            {
                "description": "the time (days) elapsed from first ESWL to the expulsion of the stone", 
                "measure": "time to stone expulsion", 
                "safety_issue": "No", 
                "time_frame": "2,4,6week"
            }, 
            {
                "description": "The number of required ESWL for the stone expulsion", 
                "measure": "Number of ESWL", 
                "safety_issue": "No", 
                "time_frame": "6week"
            }
        ], 
        "overall_contact": {
            "email": "deokhyun.han@gmail.com", 
            "last_name": "Deok Hyun Han, MD", 
            "phone": "82-2-3410-6431"
        }, 
        "overall_official": {
            "affiliation": "Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine", 
            "last_name": "Deok Hyun Han, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "South Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment success is defined as no or less than 3 mm size remnant stone", 
            "measure": "Difference of the treatment success rate in two weeks after ESWL between treatment group and placebo group", 
            "safety_issue": "No", 
            "time_frame": "2 weeks after ESWL"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011737"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "HAN, DEOK HYUN", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Treatment success is defined as no or less than 3 mm size remnant stone", 
                "measure": "Difference of the treatment success rate after ESWL between treatment group and placebo group", 
                "safety_issue": "No", 
                "time_frame": "4, 6 weeks after ESWL"
            }, 
            {
                "description": "Rate of total Adverse Events and Adverse Events relevant to Investigational drug", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "2,4,6weeks"
            }, 
            {
                "description": "visual analogue pain scale due to urinary stone", 
                "measure": "pain scale", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2, 4, 6 weeks"
            }, 
            {
                "description": "incidence of additional intervention for the urinary stone ex> ureteral stent insertion, percutaneous nephrostomy, ureteroscopic ureterolithotomy, percutaneous nephrolithotomy, laparoscopic stone removal and so on", 
                "measure": "rate of additional intervention", 
                "safety_issue": "No", 
                "time_frame": "6 week"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A ST Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}